APO010 has a unique mechanism of action, as it mimics the body’s own immune system by CTL tumor killing
APO010 binds to the FAS-receptor of the cancer cell which is expressed on most (>80%) cancers cells. It binds with a strong hexameric structure which then activates apoptosis (cell-death) of the malignant cells
Oncology Venture has developed a APO010-DRP™ Drug Response Prediction used as a precision companion diagnostic (CDx) to stratify highly likely sensitive responders, and are presently screening patients to be included in the clinical trials for Multiple Myeloma
APO010 is a potent anticancer agent with undisrupted activity in several resistant cells. APO010 mimics one of the two cytotoxic T-lymphocytes (CTLs) mechanisms of actions for efficient cancer cell killing. FasL is one of only few molecules that immune cells use to induce apoptotic cancer cell death. The Fas receptor is expressed on over 80% of cancer cells.